RE:RE:https://ceo.ca/@newswire/mountain-valley-md-proceeding-with-
As well as less dose (drug) needed, their treatment may also reduce speed recovery and so lower mortality rate from Covid as well, given this statement:
"MVMD expects that the upcoming BSL-4 lab study will demonstrate meaningful dose sparing in two important ways; a reduction in the required Active Pharmaceutical Ingredient (API) Ivermectin due to the applications of the Company's technology, and the shorter course to complete viral clearance."